Skip to main content
Top
Published in: Reviews in Endocrine and Metabolic Disorders 5/2022

23-08-2022 | Insulins

Variable phenotypes of individual and family monogenic cases with hyperinsulinism and diabetes: a systematic review

Authors: Kevin Perge, Marc Nicolino

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 5/2022

Login to get access

Abstract

Maturity-Onset Diabetes of the Youth (MODY) diabetes remains commonly misdiagnosed. A monogenic form should be suspected in individuals presenting hyperinsulinemic hypoglycemia (HH) associated with, either later development of MODY (hypoglycemia-remission-diabetes sequence), or with first/second-degree family history of diabetes. Herein, we aimed to describe this individual or family monogenic association between HH and diabetes, and identify potential genotype–phenotype correlations. We conducted a systematic review of 26 studies, including a total of 67 patients with this association resulting from variants in GCK (n = 5 cases), ABCC8 (n = 29), HNF1A (n = 5), or HNF4A (n = 28). A family history of hypoglycemia and/or diabetes was present in 91% of cases (61/67). Median age at first hypoglycemia was 24 h after birth. Diazoxide was initiated in 46 children (46/67–69%); responsiveness was found in 91% (42/46). Median HH duration was three years (1 day-25 years). Twenty-three patients (23/67–34%) later developed diabetes (median age: 13 years; range: 8–48); more frequently in those untreated with diazoxide. This association was most commonly inherited in an autosomal dominant manner (43/48–90%). Some genes were associated with less severe initial hypoglycemia (HNF1A), shorter duration of HH (HNF4A), and more maternal (ABCC8) or paternal (HNF4A) transmission. This study illustrates that the same genotype can give a biphasic phenotype in the same person or a reverse phenotype in the same family. Wider awareness of this association is necessary in pediatrics to establish annual monitoring of patients who have presented HH, and during maternity to screen diabetes and optimize genetic counseling and management of pregnancy, childbirth, and the newborn.
PROSPERO registration: CRD42020178265.
Appendix
Available only for authorised users
Literature
1.
go back to reference Naylor R, Knight Johnson A, del Gaudio D. Maturity-Onset Diabetes of the Young Overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993. http://www.ncbi.nlm.nih.gov/books/NBK500456/. Accessed 20 Apr 2020. Naylor R, Knight Johnson A, del Gaudio D. Maturity-Onset Diabetes of the Young Overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993. http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK500456/​. Accessed 20 Apr 2020.
2.
go back to reference Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53:2504–8.PubMedCrossRef Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53:2504–8.PubMedCrossRef
3.
go back to reference Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, et al. Prevalence, Characteristics and Clinical Diagnosis of Maturity Onset Diabetes of the Young Due to Mutations in HNF1A, HNF4A, and Glucokinase: Results From the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013;98:4055–62.PubMedPubMedCentralCrossRef Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, et al. Prevalence, Characteristics and Clinical Diagnosis of Maturity Onset Diabetes of the Young Due to Mutations in HNF1A, HNF4A, and Glucokinase: Results From the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013;98:4055–62.PubMedPubMedCentralCrossRef
4.
go back to reference Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, et al. Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the UK pediatric diabetes population with monogenic diabetes. Diabetes Care. 2016;39:1879–88. Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, et al. Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the UK pediatric diabetes population with monogenic diabetes. Diabetes Care. 2016;39:1879–88.
5.
go back to reference Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al. Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation. N Engl J Med. Massachusetts Medical Society; 1998;338:226–30. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al. Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation. N Engl J Med. Massachusetts Medical Society; 1998;338:226–30.
6.
go back to reference Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko H-L, Rahier J, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest. 2000;106:897–906.PubMedPubMedCentralCrossRef Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko H-L, Rahier J, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest. 2000;106:897–906.PubMedPubMedCentralCrossRef
8.
go back to reference Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4(4): e118.PubMedPubMedCentralCrossRef Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4(4): e118.PubMedPubMedCentralCrossRef
9.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34.PubMedCrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34.PubMedCrossRef
10.
go back to reference Magge SN, Shyng S-L, MacMullen C, Steinkrauss L, Ganguly A, Katz LEL, et al. Familial Leucine-Sensitive Hypoglycemia of Infancy Due to a Dominant Mutation of the β-Cell Sulfonylurea Receptor. J Clin Endocrinol Metab. 2004;89:4450–6.PubMedCrossRef Magge SN, Shyng S-L, MacMullen C, Steinkrauss L, Ganguly A, Katz LEL, et al. Familial Leucine-Sensitive Hypoglycemia of Infancy Due to a Dominant Mutation of the β-Cell Sulfonylurea Receptor. J Clin Endocrinol Metab. 2004;89:4450–6.PubMedCrossRef
11.
go back to reference Gussinyer M, Clemente M, Cebrián R, Yeste D, Albisu M, Carrascosa A. Glucose Intolerance and Diabetes Are Observed in the Long-Term Follow-Up of Nonpancreatectomized Patients With Persistent Hyperinsulinemic Hypoglycemia of Infancy Due to Mutations in the ABCC8 Gene. Diabetes Care. 2008;31:1257–9.PubMedCrossRef Gussinyer M, Clemente M, Cebrián R, Yeste D, Albisu M, Carrascosa A. Glucose Intolerance and Diabetes Are Observed in the Long-Term Follow-Up of Nonpancreatectomized Patients With Persistent Hyperinsulinemic Hypoglycemia of Infancy Due to Mutations in the ABCC8 Gene. Diabetes Care. 2008;31:1257–9.PubMedCrossRef
12.
go back to reference Abdulhadi-Atwan M, Bushmann J, Tornovsky-Babaey S, Perry A, Abu-Libdeh A, Glaser B, et al. Novel De Novo Mutation in Sulfonylurea Receptor 1 Presenting as Hyperinsulinism in Infancy Followed by Overt Diabetes in Early Adolescence. Diabetes. 2008;57:1935–40.PubMedPubMedCentralCrossRef Abdulhadi-Atwan M, Bushmann J, Tornovsky-Babaey S, Perry A, Abu-Libdeh A, Glaser B, et al. Novel De Novo Mutation in Sulfonylurea Receptor 1 Presenting as Hyperinsulinism in Infancy Followed by Overt Diabetes in Early Adolescence. Diabetes. 2008;57:1935–40.PubMedPubMedCentralCrossRef
13.
go back to reference Pinney SE, MacMullen C, Becker S, Lin Y-W, Hanna C, Thornton P, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118:2877–86.PubMedPubMedCentralCrossRef Pinney SE, MacMullen C, Becker S, Lin Y-W, Hanna C, Thornton P, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118:2877–86.PubMedPubMedCentralCrossRef
14.
go back to reference Vieira TC, Bergamin CS, Gurgel LC, Moisés RS. Hyperinsulinemic hypoglycemia evolving to gestational diabetes and diabetes mellitus in a family carrying the inactivating ABCC8 E1506K mutation. Pediatr Diabetes. 2010;11:505–8.PubMedCrossRef Vieira TC, Bergamin CS, Gurgel LC, Moisés RS. Hyperinsulinemic hypoglycemia evolving to gestational diabetes and diabetes mellitus in a family carrying the inactivating ABCC8 E1506K mutation. Pediatr Diabetes. 2010;11:505–8.PubMedCrossRef
15.
go back to reference Oçal G, Flanagan SE, Hacihamdioğlu B, Berberoğlu M, Siklar Z, Ellard S, et al. Clinical characteristics of recessive and dominant congenital hyperinsulinism due to mutation(s) in the ABCC8/KCNJ11 genes encoding the ATP-sensitive potasium channel in the pancreatic beta cell. J Pediatr Endocrinol Metab. 2011;24:1019–23.PubMedCrossRef Oçal G, Flanagan SE, Hacihamdioğlu B, Berberoğlu M, Siklar Z, Ellard S, et al. Clinical characteristics of recessive and dominant congenital hyperinsulinism due to mutation(s) in the ABCC8/KCNJ11 genes encoding the ATP-sensitive potasium channel in the pancreatic beta cell. J Pediatr Endocrinol Metab. 2011;24:1019–23.PubMedCrossRef
16.
go back to reference Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, Harmer SC, et al. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations. Diabetologia. 2011;54:2575–83.PubMedPubMedCentralCrossRef Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, Harmer SC, et al. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations. Diabetologia. 2011;54:2575–83.PubMedPubMedCentralCrossRef
17.
go back to reference Saito-Hakoda A, Yorifuji T, Kanno J, Kure S, Fujiwara I. Nateglinide is Effective for Diabetes Mellitus with Reactive Hypoglycemia in a Child with a Compound Heterozygous ABCC8 Mutation. Clin Pediatr Endocrinol. 2012;21:45–52.PubMedPubMedCentralCrossRef Saito-Hakoda A, Yorifuji T, Kanno J, Kure S, Fujiwara I. Nateglinide is Effective for Diabetes Mellitus with Reactive Hypoglycemia in a Child with a Compound Heterozygous ABCC8 Mutation. Clin Pediatr Endocrinol. 2012;21:45–52.PubMedPubMedCentralCrossRef
18.
go back to reference Harel S, Cohen ASA, Hussain K, Flanagan SE, Schlade-Bartusiak K, Patel M, et al. Alternating hypoglycemia and hyperglycemia in a toddler with a homozygous p.R1419H ABCC8 mutation: an unusual clinical picture. J Pediatr Endocrinol Metab. 2015;28:345–351. Harel S, Cohen ASA, Hussain K, Flanagan SE, Schlade-Bartusiak K, Patel M, et al. Alternating hypoglycemia and hyperglycemia in a toddler with a homozygous p.R1419H ABCC8 mutation: an unusual clinical picture. J Pediatr Endocrinol Metab. 2015;28:345–351.
19.
go back to reference Dastamani A, Güemes M, Walker J, Shah P, Hussain K. Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation. J Pediatr Endocrinol Metab. 2017;30:1219–22.PubMedCrossRef Dastamani A, Güemes M, Walker J, Shah P, Hussain K. Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation. J Pediatr Endocrinol Metab. 2017;30:1219–22.PubMedCrossRef
20.
go back to reference Işık E, Demirbilek H, Houghton JA, Ellard S, Flanagan SE, Hussain K. Congenital Hyperinsulinism and Evolution to Sulfonylurearesponsive Diabetes Later in Life due to a Novel Homozygous p.L171F ABCC8 Mutation. J Clin Res Pediatr Endocrinol. 2019;11:82–7. Işık E, Demirbilek H, Houghton JA, Ellard S, Flanagan SE, Hussain K. Congenital Hyperinsulinism and Evolution to Sulfonylurearesponsive Diabetes Later in Life due to a Novel Homozygous p.L171F ABCC8 Mutation. J Clin Res Pediatr Endocrinol. 2019;11:82–7.
21.
go back to reference Dusátková P, Průhová S, Sumník Z, Kolousková S, Obermannová B, Cinek O, et al. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. J Pediatr Endocrinol Metab. 2011;24:377–9.PubMedCrossRef Dusátková P, Průhová S, Sumník Z, Kolousková S, Obermannová B, Cinek O, et al. HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. J Pediatr Endocrinol Metab. 2011;24:377–9.PubMedCrossRef
22.
go back to reference Stanescu DE, Hughes N, Kaplan B, Stanley CA, De León DD. Novel Presentations of Congenital Hyperinsulinism due to Mutations in the MODY genes: HNF1A and HNF4A. J Clin Endocrinol Metab. 2012;97:E2026–30.PubMedPubMedCentralCrossRef Stanescu DE, Hughes N, Kaplan B, Stanley CA, De León DD. Novel Presentations of Congenital Hyperinsulinism due to Mutations in the MODY genes: HNF1A and HNF4A. J Clin Endocrinol Metab. 2012;97:E2026–30.PubMedPubMedCentralCrossRef
23.
go back to reference Tung JY, Boodhansingh K, Stanley CA, De León DD. Clinical heterogeneity of hyperinsulinism due to HNF1A and HNF4A mutations. Pediatr Diabetes. 2018;19:910–6.PubMedPubMedCentralCrossRef Tung JY, Boodhansingh K, Stanley CA, De León DD. Clinical heterogeneity of hyperinsulinism due to HNF1A and HNF4A mutations. Pediatr Diabetes. 2018;19:910–6.PubMedPubMedCentralCrossRef
24.
go back to reference Fajans SS, Bell GI. Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4α (HNF4A). Diabetologia. 2007;50:2600–1.PubMedCrossRef Fajans SS, Bell GI. Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4α (HNF4A). Diabetologia. 2007;50:2600–1.PubMedCrossRef
25.
go back to reference Kapoor RR, Locke J, Colclough K, Wales J, Conn JJ, Hattersley AT, et al. Persistent Hyperinsulinemic Hypoglycemia and Maturity-Onset Diabetes of the Young Due to Heterozygous HNF4A Mutations. Diabetes. 2008;57:1659–63.PubMedCrossRef Kapoor RR, Locke J, Colclough K, Wales J, Conn JJ, Hattersley AT, et al. Persistent Hyperinsulinemic Hypoglycemia and Maturity-Onset Diabetes of the Young Due to Heterozygous HNF4A Mutations. Diabetes. 2008;57:1659–63.PubMedCrossRef
26.
go back to reference Conn JJ, Simm PJ, Oats JJN, Nankervis AJ, Jacobs SE, Ellard S, et al. Neonatal hyperinsulinaemic hypoglycaemia and monogenic diabetes due to a heterozygous mutation of the HNF4A gene. Aust N Z J Obstet Gynaecol. 2009;49:328–30.PubMedCrossRef Conn JJ, Simm PJ, Oats JJN, Nankervis AJ, Jacobs SE, Ellard S, et al. Neonatal hyperinsulinaemic hypoglycaemia and monogenic diabetes due to a heterozygous mutation of the HNF4A gene. Aust N Z J Obstet Gynaecol. 2009;49:328–30.PubMedCrossRef
27.
go back to reference Flanagan SE, Kapoor RR, Mali G, Cody D, Murphy N, Schwahn B, et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol. 2010;162:987–92.PubMedPubMedCentralCrossRef Flanagan SE, Kapoor RR, Mali G, Cody D, Murphy N, Schwahn B, et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol. 2010;162:987–92.PubMedPubMedCentralCrossRef
28.
go back to reference Pingul MM, Hughes N, Wu A, Stanley CA, Gruppuso PA. Hepatocyte Nuclear Factor 4α Gene Mutation Associated with Familial Neonatal Hyperinsulinism and Maturity-Onset Diabetes of the Young. J Pediatr. 2011;158:852–4.PubMedCrossRef Pingul MM, Hughes N, Wu A, Stanley CA, Gruppuso PA. Hepatocyte Nuclear Factor 4α Gene Mutation Associated with Familial Neonatal Hyperinsulinism and Maturity-Onset Diabetes of the Young. J Pediatr. 2011;158:852–4.PubMedCrossRef
29.
go back to reference Colombo C, Geraci C, Suprani T, Pocecco M, Barbetti F. Macrosomia, transient neonatal hypoglycemia, and monogenic diabetes in a family with heterozygous mutation R154X of HNF4A gene. J Endocrinol Invest. 2011;34:252–3.PubMedCrossRef Colombo C, Geraci C, Suprani T, Pocecco M, Barbetti F. Macrosomia, transient neonatal hypoglycemia, and monogenic diabetes in a family with heterozygous mutation R154X of HNF4A gene. J Endocrinol Invest. 2011;34:252–3.PubMedCrossRef
30.
go back to reference Arya VB, Rahman S, Senniappan S, Flanagan SE, Ellard S, Hussain K. HNF4A mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response. Diabet Med. 2014;31:e11–5.PubMedPubMedCentralCrossRef Arya VB, Rahman S, Senniappan S, Flanagan SE, Ellard S, Hussain K. HNF4A mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response. Diabet Med. 2014;31:e11–5.PubMedPubMedCentralCrossRef
31.
go back to reference McGlacken-Byrne SM, Hawkes CP, Flanagan SE, Ellard S, McDonnell CM, Murphy NP. The evolving course of HNF4A hyperinsulinaemic hypoglycaemia—a case series. Diabet Med. 2014;31:e1-5.PubMedCrossRef McGlacken-Byrne SM, Hawkes CP, Flanagan SE, Ellard S, McDonnell CM, Murphy NP. The evolving course of HNF4A hyperinsulinaemic hypoglycaemia—a case series. Diabet Med. 2014;31:e1-5.PubMedCrossRef
32.
go back to reference Galcheva S, Al-Khawaga S, Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia. Best Pract Res Clin Endocrinol Metab. 2018;32:551–73.PubMedCrossRef Galcheva S, Al-Khawaga S, Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia. Best Pract Res Clin Endocrinol Metab. 2018;32:551–73.PubMedCrossRef
34.
go back to reference Rosenfeld E, Ganguly A, Leon DDD. Congenital hyperinsulinism disorders: Genetic and clinical characteristics. Am J Med Genet C Semin Med Genet. 2019;181:682–92.PubMedPubMedCentralCrossRef Rosenfeld E, Ganguly A, Leon DDD. Congenital hyperinsulinism disorders: Genetic and clinical characteristics. Am J Med Genet C Semin Med Genet. 2019;181:682–92.PubMedPubMedCentralCrossRef
35.
go back to reference Guerin A, Nisenbaum R, Ray JG. Use of Maternal GHb Concentration to Estimate the Risk of Congenital Anomalies in the Offspring of Women with Prepregnancy Diabetes. Diabetes Care. American Diabetes Association. 2007;30:1920–5. Guerin A, Nisenbaum R, Ray JG. Use of Maternal GHb Concentration to Estimate the Risk of Congenital Anomalies in the Offspring of Women with Prepregnancy Diabetes. Diabetes Care. American Diabetes Association. 2007;30:1920–5.
36.
go back to reference Billionnet C, Mitanchez D, Weill A, Nizard J, Alla F, Hartemann A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia. 2017;60:636–44.PubMedPubMedCentralCrossRef Billionnet C, Mitanchez D, Weill A, Nizard J, Alla F, Hartemann A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia. 2017;60:636–44.PubMedPubMedCentralCrossRef
38.
go back to reference Arnoux J-B, de Lonlay P, Ribeiro M-J, Hussain K, Blankenstein O, Mohnike K, et al. Congenital hyperinsulinism. Early Hum Dev. 2010;86:287–94.PubMedCrossRef Arnoux J-B, de Lonlay P, Ribeiro M-J, Hussain K, Blankenstein O, Mohnike K, et al. Congenital hyperinsulinism. Early Hum Dev. 2010;86:287–94.PubMedCrossRef
39.
go back to reference Gϋemes M, Rahman SA, Kapoor RR, et al. Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management [published online ahead of print, 2020 Mar 17]. Rev Endocr Metab Disord. 2020. https://doi.org/10.1007/s11154-020-09548-7. Gϋemes M, Rahman SA, Kapoor RR, et al. Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management [published online ahead of print, 2020 Mar 17]. Rev Endocr Metab Disord. 2020. https://​doi.​org/​10.​1007/​s11154-020-09548-7.
40.
go back to reference Palladino AA, Bennett MJ, Stanley CA. Hyperinsulinism in Infancy and Childhood: When an Insulin Level Is Not Always Enough. Clin Chem Oxford Academic. 2008;54:256–63.CrossRef Palladino AA, Bennett MJ, Stanley CA. Hyperinsulinism in Infancy and Childhood: When an Insulin Level Is Not Always Enough. Clin Chem Oxford Academic. 2008;54:256–63.CrossRef
41.
go back to reference De León DD, Stanley CA. Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia. Best Pract Res Clin Endocrinol Metab. 2013;27:763–9.PubMedPubMedCentralCrossRef De León DD, Stanley CA. Determination of insulin for the diagnosis of hyperinsulinemic hypoglycemia. Best Pract Res Clin Endocrinol Metab. 2013;27:763–9.PubMedPubMedCentralCrossRef
42.
go back to reference Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children. J Pediatr. 2016;168:212–9.PubMedCrossRef Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children. J Pediatr. 2016;168:212–9.PubMedCrossRef
43.
go back to reference Herrera A, Vajravelu ME, Givler S, Mitteer L, Avitabile CM, Lord K, et al. Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. J Clin Endocrinol Metab. 2018;103:4365–72.PubMedPubMedCentralCrossRef Herrera A, Vajravelu ME, Givler S, Mitteer L, Avitabile CM, Lord K, et al. Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. J Clin Endocrinol Metab. 2018;103:4365–72.PubMedPubMedCentralCrossRef
44.
go back to reference El Hajj N, Schneider E, Lehnen H, Haaf T. Epigenetics and life-long consequences of an adverse nutritional and diabetic intrauterine environment. Reproduction. 2014;148(6):R111–20.PubMedPubMedCentralCrossRef El Hajj N, Schneider E, Lehnen H, Haaf T. Epigenetics and life-long consequences of an adverse nutritional and diabetic intrauterine environment. Reproduction. 2014;148(6):R111–20.PubMedPubMedCentralCrossRef
45.
go back to reference Steele AM, Wensley KJ, Ellard S, Murphy R, Shepherd M, Colclough K, et al. Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies. PLOS ONE. 2013;8:e65326. Steele AM, Wensley KJ, Ellard S, Murphy R, Shepherd M, Colclough K, et al. Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies. PLOS ONE. 2013;8:e65326.
46.
go back to reference Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab. Oxford Academic. 1995;80:386–92. Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab. Oxford Academic. 1995;80:386–92.
47.
go back to reference Glaser B, Ryan F, Donath M, Landau H, Stanley CA, Baker L, et al. Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Diabetes. 1999;48:1652–7.PubMedCrossRef Glaser B, Ryan F, Donath M, Landau H, Stanley CA, Baker L, et al. Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Diabetes. 1999;48:1652–7.PubMedCrossRef
48.
go back to reference Straub SG, Cosgrove KE, Ämmälä C, Shepherd RM, O’Brien RE, Barnes PD, et al. Hyperinsulinism of Infancy: The Regulated Release of Insulin by KATP Channel—Independent Pathways. Diabetes. 2001;50:329–39.PubMedCrossRef Straub SG, Cosgrove KE, Ämmälä C, Shepherd RM, O’Brien RE, Barnes PD, et al. Hyperinsulinism of Infancy: The Regulated Release of Insulin by KATP Channel—Independent Pathways. Diabetes. 2001;50:329–39.PubMedCrossRef
49.
go back to reference Seghers V, Nakazaki M, DeMayo F, Aguilar-Bryan L, Bryan J. Sur1 Knockout Mice A model for KATP channel-independent regulation of insulin secretion. J Biol Chem. 2000;275:9270–7.PubMedCrossRef Seghers V, Nakazaki M, DeMayo F, Aguilar-Bryan L, Bryan J. Sur1 Knockout Mice A model for KATP channel-independent regulation of insulin secretion. J Biol Chem. 2000;275:9270–7.PubMedCrossRef
50.
go back to reference Remedi MS, Rocheleau JV, Tong A, Patton BL, McDaniel ML, Piston DW, et al. Hyperinsulinism in mice with heterozygous loss of KATP channels. Diabetologia. 2006;49:2368–78.PubMedCrossRef Remedi MS, Rocheleau JV, Tong A, Patton BL, McDaniel ML, Piston DW, et al. Hyperinsulinism in mice with heterozygous loss of KATP channels. Diabetologia. 2006;49:2368–78.PubMedCrossRef
51.
go back to reference Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes. 2000;49:1325–33.PubMedCrossRef Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes. 2000;49:1325–33.PubMedCrossRef
52.
go back to reference Rahman SA, Nessa A, Hussain K. Molecular mechanisms of congenital hyperinsulinism. J Mol Endocrinol. 2015;54:R119–29.PubMedCrossRef Rahman SA, Nessa A, Hussain K. Molecular mechanisms of congenital hyperinsulinism. J Mol Endocrinol. 2015;54:R119–29.PubMedCrossRef
53.
go back to reference Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J Clin Invest. 1992;90:320–5.PubMedPubMedCentralCrossRef Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J Clin Invest. 1992;90:320–5.PubMedPubMedCentralCrossRef
54.
go back to reference Timsit J, Bellanné-Chantelot C, Velho G. Diabètes de type MODY. EMC Elsevier SAS. 2006;3:1–7. Timsit J, Bellanné-Chantelot C, Velho G. Diabètes de type MODY. EMC Elsevier SAS. 2006;3:1–7.
55.
go back to reference Olson LK, Redmon JB, Towle HC, Robertson RP. Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest. 1993;92:514–9.PubMedPubMedCentralCrossRef Olson LK, Redmon JB, Towle HC, Robertson RP. Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest. 1993;92:514–9.PubMedPubMedCentralCrossRef
56.
go back to reference Petrelli A, Giovenzana A, Insalaco V, Phillips BE, Pietropaolo M, Giannoukakis N. Autoimmune Inflammation and Insulin Resistance: Hallmarks So Far and Yet So Close to Explain Diabetes Endotypes. Curr Diab Rep. 2021;21:54.PubMedPubMedCentralCrossRef Petrelli A, Giovenzana A, Insalaco V, Phillips BE, Pietropaolo M, Giannoukakis N. Autoimmune Inflammation and Insulin Resistance: Hallmarks So Far and Yet So Close to Explain Diabetes Endotypes. Curr Diab Rep. 2021;21:54.PubMedPubMedCentralCrossRef
57.
go back to reference Weng J, Ekelund M, Lehto M, Li H, Ekberg G, Frid A, et al. Screening for MODY Mutations, GAD Antibodies, and Type 1 Diabetes– Associated HLA Genotypes in Women With Gestational Diabetes Mellitus. Diabetes Care. 2002;25:68–71.PubMedCrossRef Weng J, Ekelund M, Lehto M, Li H, Ekberg G, Frid A, et al. Screening for MODY Mutations, GAD Antibodies, and Type 1 Diabetes– Associated HLA Genotypes in Women With Gestational Diabetes Mellitus. Diabetes Care. 2002;25:68–71.PubMedCrossRef
58.
go back to reference Bowman P, Flanagan SE, Edghill EL, Damhuis A, Shepherd MH, Paisey R, et al. Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia. 2012;55:123–7.PubMedCrossRef Bowman P, Flanagan SE, Edghill EL, Damhuis A, Shepherd MH, Paisey R, et al. Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia. 2012;55:123–7.PubMedCrossRef
59.
go back to reference Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, et al. Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young. Diabetes Care. 2012;35:1206–12.PubMedPubMedCentralCrossRef Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ, et al. Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the Young. Diabetes Care. 2012;35:1206–12.PubMedPubMedCentralCrossRef
60.
go back to reference Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of Vascular Complications Among Patients With Glucokinase Mutations and Prolonged, Mild Hyperglycemia. JAMA. 2014;311:279–86. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of Vascular Complications Among Patients With Glucokinase Mutations and Prolonged, Mild Hyperglycemia. JAMA. 2014;311:279–86.
61.
go back to reference Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2014;57:54–6.PubMedCrossRef Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia. 2014;57:54–6.PubMedCrossRef
62.
go back to reference Chakera AJ, Steele AM, Gloyn AL, Shepherd MH, Shields B, Ellard S, et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care. 2015;38:1383–92.PubMedCrossRef Chakera AJ, Steele AM, Gloyn AL, Shepherd MH, Shields B, Ellard S, et al. Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care. 2015;38:1383–92.PubMedCrossRef
63.
go back to reference Peter S. Acarbose and Idiopathic Reactive Hypoglycemia. HRP Karger Publishers. 2003;60:166–7. Peter S. Acarbose and Idiopathic Reactive Hypoglycemia. HRP Karger Publishers. 2003;60:166–7.
64.
go back to reference Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the Genes Encoding the Transcription Factors Hepatocyte Nuclear Factor 1 Alpha and 4 Alpha in Maturity-Onset Diabetes of the Young and Hyperinsulinemic Hypoglycemia. Hum Mutat. 2013;34:669–85.PubMedCrossRef Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the Genes Encoding the Transcription Factors Hepatocyte Nuclear Factor 1 Alpha and 4 Alpha in Maturity-Onset Diabetes of the Young and Hyperinsulinemic Hypoglycemia. Hum Mutat. 2013;34:669–85.PubMedCrossRef
65.
go back to reference Harries LW, Locke JM, Shields B, Hanley NA, Hanley KP, Steele A, et al. The Diabetic Phenotype in HNF4A Mutation Carriers Is Moderated By the Expression of HNF4A Isoforms From the P1 Promoter During Fetal Development. Diabet Med. 2008;57:1745–52.CrossRef Harries LW, Locke JM, Shields B, Hanley NA, Hanley KP, Steele A, et al. The Diabetic Phenotype in HNF4A Mutation Carriers Is Moderated By the Expression of HNF4A Isoforms From the P1 Promoter During Fetal Development. Diabet Med. 2008;57:1745–52.CrossRef
66.
go back to reference Hewat TI, Laver TW, Houghton JAL, Männistö JME, Alvi S, Brearey SP, et al. Increased referrals for congenital hyperinsulinism genetic testing in children with trisomy 21 reflects the high burden of non-genetic risk factors in this group. Pediatr Diabetes. 2022;23:457–61.PubMedPubMedCentralCrossRef Hewat TI, Laver TW, Houghton JAL, Männistö JME, Alvi S, Brearey SP, et al. Increased referrals for congenital hyperinsulinism genetic testing in children with trisomy 21 reflects the high burden of non-genetic risk factors in this group. Pediatr Diabetes. 2022;23:457–61.PubMedPubMedCentralCrossRef
67.
go back to reference Rubio-Cabezas O, Hattersley AT, Njølstad PR, Mlynarski W, Ellard S, White N, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014;15:47–64.PubMedCrossRef Rubio-Cabezas O, Hattersley AT, Njølstad PR, Mlynarski W, Ellard S, White N, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014;15:47–64.PubMedCrossRef
68.
go back to reference Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, et al. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A–MODY cohort. Diabet Med. 2016;33:976–84.PubMedCrossRef Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, et al. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A–MODY cohort. Diabet Med. 2016;33:976–84.PubMedCrossRef
69.
go back to reference Bacon S, Kyithar MP, Condron EM, Vizzard N, Burke M, Byrne MM. Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood. Acta Diabetol. 2016;53:965–72. Bacon S, Kyithar MP, Condron EM, Vizzard N, Burke M, Byrne MM. Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood. Acta Diabetol. 2016;53:965–72.
70.
go back to reference Haddouche A, Bellanne-Chantelot C, Rod A, Fournier L, Chiche L, Gautier J-F, et al. Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series. J Diabetes. 2020;12:48–57.PubMedCrossRef Haddouche A, Bellanne-Chantelot C, Rod A, Fournier L, Chiche L, Gautier J-F, et al. Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series. J Diabetes. 2020;12:48–57.PubMedCrossRef
71.
go back to reference GoodSmith MS, Skandari MR, Huang ES, Naylor RN. The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing. Diabetes Care. 2019;42:2247–55.PubMedPubMedCentralCrossRef GoodSmith MS, Skandari MR, Huang ES, Naylor RN. The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing. Diabetes Care. 2019;42:2247–55.PubMedPubMedCentralCrossRef
72.
go back to reference Liljeström B, Tuomi T, Isomaa B, Sarelin L, Aktan-Collan K, Kääriäinen H. Adolescents at Risk for MODY3 Diabetes Prefer Genetic Testing Before Adulthood. Diabetes Care. 2007;30:1571–3.PubMedCrossRef Liljeström B, Tuomi T, Isomaa B, Sarelin L, Aktan-Collan K, Kääriäinen H. Adolescents at Risk for MODY3 Diabetes Prefer Genetic Testing Before Adulthood. Diabetes Care. 2007;30:1571–3.PubMedCrossRef
73.
go back to reference Bosma AR, Rigter T, Weinreich SS, Cornel MC, Henneman L. A genetic diagnosis of maturity-onset diabetes of the young (MODY): experiences of patients and family members. Diabet Med. 2015;32:1385–92.PubMedCrossRef Bosma AR, Rigter T, Weinreich SS, Cornel MC, Henneman L. A genetic diagnosis of maturity-onset diabetes of the young (MODY): experiences of patients and family members. Diabet Med. 2015;32:1385–92.PubMedCrossRef
74.
go back to reference Kaffel N, Chakroun E, Dammak M, Mnif M, Smaoui M, Charfi N, et al. Inhibition paradoxale de la réponse somatotrope et corticotrope à l’hypoglycémie par hyperinsulinisme endogène: à propos d’une observation. Paradoxal growth hormone and cortisol response to hypoglycemia caused by endogenous hyperinsulinemia: a case report]. Ann Endocrinol (Paris). 2007;68:204–7. Kaffel N, Chakroun E, Dammak M, Mnif M, Smaoui M, Charfi N, et al. Inhibition paradoxale de la réponse somatotrope et corticotrope à l’hypoglycémie par hyperinsulinisme endogène: à propos d’une observation. Paradoxal growth hormone and cortisol response to hypoglycemia caused by endogenous hyperinsulinemia: a case report]. Ann Endocrinol (Paris). 2007;68:204–7.
75.
go back to reference Hussain K, Hindmarsh P, Aynsley-Green A. Neonates with Symptomatic Hyperinsulinemic Hypoglycemia Generate Inappropriately Low Serum Cortisol Counterregulatory Hormonal Responses. J Clin Endocrinol. 2003;88:4342–7.CrossRef Hussain K, Hindmarsh P, Aynsley-Green A. Neonates with Symptomatic Hyperinsulinemic Hypoglycemia Generate Inappropriately Low Serum Cortisol Counterregulatory Hormonal Responses. J Clin Endocrinol. 2003;88:4342–7.CrossRef
Metadata
Title
Variable phenotypes of individual and family monogenic cases with hyperinsulinism and diabetes: a systematic review
Authors
Kevin Perge
Marc Nicolino
Publication date
23-08-2022
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 5/2022
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-022-09749-2

Other articles of this Issue 5/2022

Reviews in Endocrine and Metabolic Disorders 5/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine